Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has highlighted the need for vaccines that not only prevent disease but also prevent transmission. Parenteral vaccines induce robust systemic immunity but poor immunity at the respiratory mucosa. We developed a vaccine strategy that we call "prime and spike," which leverages existing immunity generated by primary vaccination (prime) to elicit mucosal immune memory within the respiratory tract by using unadjuvanted intranasal spike boosters (spike). We show that prime and spike induces robust resident memory B and T cell responses, induces immunoglobulin A at the respiratory mucosa, boosts systemic immunity, and completely protects mice with partial immunity from lethal SARS-CoV-2 infection. Using divergent spike proteins, prime and spike enables the induction of cross-reactive immunity against sarbecoviruses.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:378 |
|---|---|
| Enthalten in: |
Science (New York, N.Y.) - 378(2022), 6622 vom: 25. Nov., Seite eabo2523 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mao, Tianyang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 29.11.2022 Date Revised 06.02.2024 published: Print-Electronic UpdateOf: bioRxiv. 2022 Jan 26;:. - PMID 35118464 Citation Status MEDLINE |
|---|
| doi: |
10.1126/science.abo2523 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348164440 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348164440 | ||
| 003 | DE-627 | ||
| 005 | 20240206231833.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/science.abo2523 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1282.xml |
| 035 | |a (DE-627)NLM348164440 | ||
| 035 | |a (NLM)36302057 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mao, Tianyang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2022 | ||
| 500 | |a Date Revised 06.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: bioRxiv. 2022 Jan 26;:. - PMID 35118464 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has highlighted the need for vaccines that not only prevent disease but also prevent transmission. Parenteral vaccines induce robust systemic immunity but poor immunity at the respiratory mucosa. We developed a vaccine strategy that we call "prime and spike," which leverages existing immunity generated by primary vaccination (prime) to elicit mucosal immune memory within the respiratory tract by using unadjuvanted intranasal spike boosters (spike). We show that prime and spike induces robust resident memory B and T cell responses, induces immunoglobulin A at the respiratory mucosa, boosts systemic immunity, and completely protects mice with partial immunity from lethal SARS-CoV-2 infection. Using divergent spike proteins, prime and spike enables the induction of cross-reactive immunity against sarbecoviruses | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Immunoglobulin A |2 NLM | |
| 700 | 1 | |a Israelow, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Peña-Hernández, Mario A |e verfasserin |4 aut | |
| 700 | 1 | |a Suberi, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Liqun |e verfasserin |4 aut | |
| 700 | 1 | |a Luyten, Sophia |e verfasserin |4 aut | |
| 700 | 1 | |a Reschke, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Huiping |e verfasserin |4 aut | |
| 700 | 1 | |a Homer, Robert J |e verfasserin |4 aut | |
| 700 | 1 | |a Saltzman, W Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Iwasaki, Akiko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science (New York, N.Y.) |d 1880 |g 378(2022), 6622 vom: 25. Nov., Seite eabo2523 |w (DE-627)NLM000023450 |x 1095-9203 |7 nnns |
| 773 | 1 | 8 | |g volume:378 |g year:2022 |g number:6622 |g day:25 |g month:11 |g pages:eabo2523 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/science.abo2523 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 378 |j 2022 |e 6622 |b 25 |c 11 |h eabo2523 | ||